Morbidity and mortality of lobectomy or pneumonectomy after neoadjuvant treatment: an analysis from the ESTS database
- 22 October 2019
- journal article
- conference paper
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 57 (4) , 740-746
Abstract
To evaluate the postoperative complications and 30-day mortality rates associated with neoadjuvant chemotherapy before major anatomic lung resections registered in the European Society of Thoracic Surgeons (ESTS) database. Retrospective analysis on 52 982 anatomic lung resections registered in the ESTS database (July 2007–31 December 2017) (6587 pneumonectomies and 46 395 lobectomies); 5143 patients received neoadjuvant treatment (9.7%) (3993 chemotherapy alone and 1150 chemoradiotherapy). To adjust for possible confounders, a propensity case-matched analysis was performed. The postoperative outcomes (morbidity and 30-day mortality) of matched patients with and without induction treatment were compared. 8.2% of all patients undergoing lobectomies and 20% of all patients undergoing pneumonectomies received induction treatment. Lobectomy analysis: propensity score analysis yielded 3824 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the neoadjuvant group (626 patients, 16% vs 446 patients, 12%, P < 0.001), but 30-day mortality rates were similar (71 patients, 1.9% vs 75 patients, 2.0%, P = 0.73). The incidence of bronchopleural fistula and prolonged air leak >5 days were similar between the 2 groups (neoadjuvant: 0.5% vs 0.4%, P = 0.87; 9.2% vs 9.9%, P = 0.27). Pneumonectomy analysis: propensity score analysis yielded 1312 pairs of patients with and without induction treatment. The incidence of cardiopulmonary complications was higher in the treated patients compared to those without neoadjuvant treatment (neoadjuvant 275 cases, 21% vs 18%, P = 0.030). However, the 30-day mortality was similar between the matched groups (neoadjuvant 68 cases, 5.2% vs 5.3%, P = 0.86). Finally, the incidence of bronchopleural fistula was also similar between the 2 groups (neoadjuvant 1.8% vs 1.4%, P = 0.44). Neoadjuvant chemotherapy is not associated with an increased perioperative risk after either lobectomy or pneumonectomy, warranting a more liberal use of this approach for patients with locally advanced operable lung cancer.Keywords
Funding Information
- NIH
This publication has 26 references indexed in Scilit:
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2019
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung CancerJournal of Thoracic Oncology, 2018
- Neoadjuvant PD-1 Blockade in Resectable Lung CancerNew England Journal of Medicine, 2018
- Statistical primer: propensity score matching and its alternatives†European Journal of Cardio-Thoracic Surgery, 2018
- The Society of Thoracic Surgeons and The European Society of Thoracic Surgeons General Thoracic Surgery Databases: Joint Standardization of Variable Definitions and TerminologyThe Annals of Thoracic Surgery, 2015
- Treatment of Stage III Non-small Cell Lung CancerChest, 2013
- Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis of Randomized TrialsJournal of Thoracic Oncology, 2009
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialThe Lancet, 2009
- A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin useStatistics in Medicine, 2005